Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06159673 · ClinicalTrials.gov registry record · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
A Phase 2 study of Alzheimer's Disease Psychosis, sponsored by ACADIA Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,074
- Enrollment target
- 20
- Study locations
NCT06159673 is a Phase 2 study of Alzheimer's Disease Psychosis that is actively recruiting participants, run by ACADIA Pharmaceuticals. The registered enrollment target is 1,074 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT06159673, a Phase 2 study of Alzheimer's Disease Psychosis, is actively recruiting participants, sponsored by ACADIA Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,074 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP * Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first. * Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B will be performed independently of each other and will commence after enrollment of Part 1. All 3 substudies will be analyzed independently of each other. Each substudy individually will consist of a screening period (up to 49 days); a double-blind treatment period (6 weeks); a safety follow-up period (30 days) for patients not rolling over into an open-label extension study; and vital status follow-up (for patients who terminated their substudy early).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ACP-204
Study Locations (20)
Florida
- Humanity Clinical Research Corp - Aventura
- Arrow Clinical Trials - Daytona Beach
- First Excellent Research Group - Doral
- New Life Medical Research Center Inc. - Hialeah
- Reliable Clinical Research LLC. - Hialeah
- Homestead Associates in Research Inc. - Miami
- Premier Clinical Research Institute, Inc. - Miami
- Central Miami Medical Institute - Miami
- Advanced Clinical Research Network, Corp - Miami
- Verus Clinical Research - Miami
- Future Care Solution, LLC - Miami
- MediClear Medical & Research Center, Inc. - Miami
- ABBA Medical Group LLC - Miami
- Visionary Investigators Network - Miami
California
- Advanced Research Center, Inc. - Anaheim
- ATP Clinical Research - Costa Mesa
- Neuro-Pain Medical Center - Fresno
- National Institute of Clinical Research - Garden Grove
Arizona
- Chandler Clinical Trials - Chandler
- Clinical Endpoint LLC - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,074 participants |
| Start Date | 2023-11-14 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06159673
The ClinicalTrials.gov registry entry for NCT06159673 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,074 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer's Disease Psychosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06159673 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06159673 about?
NCT06159673 is a clinical study titled "ACP-204 in Adults With Alzheimer's Disease Psychosis". This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP * Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiat...
What is the current status of trial NCT06159673?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,074 participants. The study started on 2023-11-14. Estimated completion is 2028-02.
What conditions does trial NCT06159673 study?
This clinical trial studies the following conditions: Alzheimer's Disease Psychosis.
What interventions are being tested in trial NCT06159673?
The interventions under investigation include: Placebo (DRUG), ACP-204 (DRUG).
Who is sponsoring clinical trial NCT06159673?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06159673 being conducted?
This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.